The Roles of Tissue Factor in Malignant Gliomas
Completed
- Conditions
- Venous ThromboembolismBrain Tumors
- Registration Number
- NCT00201903
- Lead Sponsor
- Ontario Clinical Oncology Group (OCOG)
- Brief Summary
To explore the relationship between tissue factor levels, tumour progression, activation of blood coagulation and venous thromboembolism with malignant glioma
- Detailed Description
To explore the relationship between tissue factor levels, tumour progression, activation of blood coagulation and venous thromboembolism with malignant glioma
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- participation in PRODIGE
- adult patients
- newly diagnosed, biopsy-confirmed grade III/IV malignant gliomas
- undergone craniotomy or stereotactic biopsy > 2 days and < 4 weeks before
Exclusion Criteria
- have known hereditary thrombophilia
- are receiving experimental antiangiogenic therapy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States
Huntsman Cancer Institute
🇺🇸Salt Lake City, Utah, United States
Toronto-Sunnybrook Regional Cancer Centre
🇨🇦Toronto, Ontario, Canada
Princess Margaret Hospital
🇨🇦Toronto, Ontario, Canada
CancerCare Manitoba
🇨🇦Winnipeg, Manitoba, Canada
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada